X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
The ongoing Phase 1/2 GLORIA trial, evaluating NOX-A12 in combination with radiotherapy in first-line MGMT unmethylated brain cancer patients, has already reported positive data from the first 2 cohorts of 3 patients each treated with weekly doses of 200 and 400 mg of NOX-A12.
Lead Product(s): Olaptesed Pegol,Radiotherapy
Therapeutic Area: Oncology Product Name: NOX-A12
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 05, 2021
Details:
This phase 2 study will evaluate the safety and efficacy of NOX-A12, the anti-CXCL12 agent from NOXXON, in combination with KEYTRUDA and two different chemotherapy regimens in patients with metastatic pancreatic cancer with stable microsatellites.
Lead Product(s): Olaptesed Pegol,Pembrolizumab,Gemcitabine
Therapeutic Area: Oncology Product Name: NOX-A12
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 21, 2021
Details:
As NOXXON advances its pipeline with upcoming start of clinical trials this additional liquidity will focus on manufacturing of NOX-A12 clinical trial supply in anticipation of upcoming clinical trials.
Lead Product(s): Olaptesed Pegol,Pembrolizumab,Irinotecan Hydrochloride
Therapeutic Area: Oncology Product Name: NOX-A12
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: ATLAS PHARMS LLC
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing June 01, 2021
Details:
The Phase 1/2 clinical study is testing three dose regimens of NOX-A12 (200, 400 and 600 mg/week), each combined with external-beam radiotherapy, in newly diagnosed brain cancer patients.
Lead Product(s): Olaptesed Pegol
Therapeutic Area: Oncology Product Name: NOX-A12
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 15, 2021
Details:
The study investigates three dose regimens of NOX-A12 (200, 400 and 600 mg/week), each combined with external-beam radiotherapy in newly diagnosed brain cancer patients.
Lead Product(s): Olaptesed Pegol
Therapeutic Area: Oncology Product Name: NOX-A12
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
Details:
The clinical Phase 1/2 trial investigates three dose regimens of NOX-A12 (200, 400 and 600 mg/week), each combined with external-beam radiotherapy in newly diagnosed brain cancer patients.
Lead Product(s): Olaptesed Pegol
Therapeutic Area: Oncology Product Name: NOX-A12
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 20, 2020
Details:
The enhanced immune response and long survival times for certain late-stage patients combined with the good overall safety profile confirmed in the final data support further development of the combinations containing NOX-A12 plus pembrolizumab.
Lead Product(s): Olaptesed Pegol,Pembrolizumab
Therapeutic Area: Oncology Product Name: NOX-A12
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 17, 2020
Details:
NOXXON to present poster titled “Phase 1/2 study with CXCL12 inhibitor NOX-A12 and pembrolizumab in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer".
Lead Product(s): Olaptesed Pegol,Pembrolizumab
Therapeutic Area: Oncology Product Name: NOX-A12
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 12, 2020
Details:
The Phase 1/2 clinical trial is testing three dose regimens of NOX-A12 (200, 400 and 600 mg/week), each combined with external-beam radiotherapy, in newly diagnosed brain cancer patients.
Lead Product(s): Olaptesed Pegol,Radiotherapy
Therapeutic Area: Oncology Product Name: NOX-A12
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 24, 2020
Details:
The study investigates three dose regimens of NOX-A12 (200, 400 and 600 mg/week), each combined with external-beam radiotherapy in newly diagnosed brain cancer patients.
Lead Product(s): Olaptesed Pegol,Radiotherapy
Therapeutic Area: Oncology Product Name: NOX-A12
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 30, 2020
Details:
The Financing gives the company the flexibility to consider new projects creating value with NOXXON compounds in addition to the ongoing NOX-A12 Phase 1/2 trial.
Lead Product(s): Olaptesed Pegol
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: NYIP
Deal Size: $5.9 million Upfront Cash: Undisclosed
Deal Type: Private Placement May 08, 2020
Details:
Data Safety Monitoring Board (DSMB) has confirmed that it is safe to start patient recruitment for the middle dose cohort for the Phase 1/2 NOX-A12 plus radiotherapy brain cancer trial.
Lead Product(s): Olaptesed Pegol
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 24, 2020
Details:
The financing would allow NOXXON to finance its clinical activities including completion of the brain cancer trial and manufacturing of additional drug supply for upcoming trials.
Lead Product(s): Olaptesed Pegol
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Atlas Special Opportunities
Deal Size: $15.4 Million Upfront Cash: Undisclosed
Deal Type: Financing April 23, 2020
Details:
The company presented data of its Phase 1/2 study with CXCL12 inhibitor NOX-A12 and pembrolizumab in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer.
Lead Product(s): Olaptesed Pegol,Pembrolizumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 14, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
